Share: 
Status: 
Active
Rating: 
No votes yet
0

On Demand 2016 Modern Therapies for Allergic Skin Diseases (MOC)

Course description

You can earn up to 1.5 AMA PRA Category 1 Credit(s)™. This activity has also been designated by the ABAI for 1.5 MOC Part II Self-Assessment credits. 

This session covers current and emerging therapies for atopic dermatitis, especially the most difficult ones. Newer biologics are developed or being developed for atopic dermatitis and pruritus. There is an increasing role of the allergist in the management of eczemas and contact dermatitis. Crucial to this role is an understanding of the intricacies of patch testing and the common chemical sensitizers found in cosmetics, household products and in various occupational settings.

Release Date: 12/01/2016
Expiration Date: 11/30/2019

Accreditation

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Learning objectives: 
  • Determine appropriate treatment options and which biologic therapies will benefit patients with atopic dermatitis
  • Discuss the evolving role of the allergist in the diagnosis of contact dermatitis
  • Discuss the approach to patients with pruritus and identify new treatment modalities which will be useful to treat pruritus and other allergic skin diseases
Credits
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Attendance
  • 1.50 MOC
Additional information
Disclosure: 
Luz S. Fonacier, MD, FACAAI, Moderator – Consultant/Advisor: Regeneron, Church and Dwight; Speaker: Baxter;  Supported/Contracted Research: Baxter, Genentech, Merck
 
Lawrence F. Eichenfield, MD – Consultant/Advisor: Anacor, Celgene, Genentech, Otsuka, Regeneron; Supported/Contracted Research: Astellas, Regeneron; Ownership Interest: TopMD
 
Gil Yosipovitch, MD – Consultant/Advisor: Anacor, Celgene, Eli Lilly, Johnson & Johnson, Pfizer, Regeneron; Supported/ Contracted Research: Allergan, GlaxoSmithKline, Pfizer, Roche
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Attendance
  • 1.50 MOC
Course opens: 
12/01/2016
Course expires: 
11/30/2019
Cost:
$45.00
Please login or create an account to take this course.

Payment required

You must purchase this course.